GlassScriptPhysician profile
Mary Barbara
NPI 1497195614
$3,681.26
in general payments reported to CMS, 2019-2025
23 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $136 · 2021: $511 · 2022: $19.70 · 2023: $348 · 2024: $1,167 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,014.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $976.50 | 2020-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $473.28 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.49 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $329.88 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $269.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $235.02 | 2023-2025 | Zenpep |
| Lilly USA, LLC | $182.55 | 2023-2025 | Omvoh |
| Genzyme Corporation | $139.75 | 2023-2025 | |
| Braintree Laboratories, INC. | $115.48 | 2023-2025 | Sutab |
| Nestle Healthcare Nutrition INC. | $109.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $98.92 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $58.80 | 2024 | Voquezna |
| Boston Scientific Corporation | $55.41 | 2021-2025 | General - Polypectomy |
| Pfizer INC. | $53.84 | 2023-2025 | |
| Ardelyx, INC. | $53.45 | 2024-2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $36.01 | 2023-2025 | |
| Enterra Medical, INC. | $31.31 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $25.77 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $16.49 | 2024 | |
| Olympus America INC. | $15.85 | 2024 | Endoclot Phs |
| Paratek Pharmaceuticals, INC. | $14.60 | 2024 | Nuzyra |
| Vivus LLC | $14.47 | 2023 | Qsymia |
| Celgene Corporation | $13.56 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Barbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.